{"url_path":"/sec/asbp/8-k/2026-06-12/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-12","source_url":"https://www.sec.gov/Archives/edgar/data/1847345/0001493152-26-028386-index.html","accession_number":"0001493152-26-028386","cik":"0001847345","ticker":"ASBP","issuer_name":"Aspire Biopharma Holdings, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1847345/0001493152-26-028386-index.html","primary_entity_key":"0001847345","primary_entity_name":"Aspire Biopharma Holdings, Inc."},"word_count":111,"has_tables":true,"body_markdown":"**Item\n7.01 Regulation FD Disclosure.**\n\n \n\nOn\nJune 12, 2026, the Company issued a press release, a copy of which is furnished as Exhibit 99.1 to this Form 8-K.\n\n \n\nThe\ninformation furnished pursuant to this Item 7.01, including Exhibit 99.1 shall not be deemed “filed” for purposes of\nSection 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the\nliabilities of that section, and shall not be deemed to be incorporated by reference into any filing of the Company under the\nSecurities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such\nfiling."}